Research on prostate cancer biology, detection, and outcomes. Covers genetic clues, DNA damage, diet and survival, and screening awareness.
Researchers found GZ17-6.02 alone and in combination with standard-of-care agents was effective in killing MF cells, activating key pathways including ATM, AMPK, NFκB, and macroautophagy. The compound's unique multi-factorial mechanism suggests potential for treating mycosis fungoides.
Researchers from Florida Atlantic University found that alpha-santalol, a compound in sandalwood oil, decreases cell proliferation and induces apoptosis to prevent prostate cancer development. The study showed a 53% increase in normal tissue area in treated mice, indicating protection against prostate cancer progression.
A study of over 3,500 men with prostate cancer found that a plant-based diet significantly improved measures of sexual function, urinary health, and vitality scores. The research suggests that adding more fruits and vegetables to the diet while reducing meat and dairy can have a positive impact on quality of life.
A study reveals that Rucaparib and its metabolite M324 have differentiated activities, with M324 reducing α-synuclein accumulation in neurons from Parkinson's patients. This synergy could lead to new opportunities for treating prostate cancer and potentially developing treatments for Parkinson's.
A study published in The Journal of Urology reports that racial representation matters to Black patients seeking prostate cancer information online. This lack of representation can lead to mistrust and discourage screening among Black men, who have higher rates of prostate cancer compared to White or Hispanic men.
Researchers at Northwestern University found a significant decrease in screenings for prostate cancer and urinary tract infections after implementing point-of-care alerts. The study showed a 9% reduction in PSA screenings and a 5.5% reduction in urine testing, with minimal changes in overtreatment of blood sugar.
A team of researchers from Wayne State University received a $1.4 million grant to investigate the role of cytochrome c in prostate cancer aggressiveness and the Warburg effect. The study aims to establish novel therapeutic targets to overcome treatment resistance.
Researchers discovered that depletion of the protein DPYSL5 can restore drug-responsive neuroendocrine prostate cancer cells, promoting cell transformation and lineage plasticity. This finding could lead to the development of new cancer drugs.
Researchers at Germans Trias i Pujol Research Institute have identified a combination of drugs that could change the treatment of patients with prostate cancer resistant to docetaxel. The study proposes a new treatment based on a combination of kinase inhibitors in patients who inevitably stop responding to docetaxel.
Research found a strong association between annual improvements in cardiorespiratory fitness and reduced risk of developing prostate cancer. Men with higher levels of fitness were 35% less likely to develop the disease than those with declining fitness. The study suggests encouraging physical activity may help lower prostate cancer risk.
Researchers have identified UCHL1, a protein found in highly aggressive neuroendocrine carcinomas and neuroblastoma, as a potential molecular biomarker for diagnosing these cancers and predicting responses to therapy. Targeting UCHL1 with inhibitors has been shown to delay the growth and spread of these tumors in pre-clinical models.
A recent study published in Cell Reports reveals that cancer cells can prevent the immune system from attacking them by inhibiting key checkpoints. Researchers found that monotherapy agents targeting these checkpoints may not be effective without an inflammatory trigger, explaining why some immunotherapies work while others fail.
Researchers at São Paulo State University found a link between a protein-poor diet during pregnancy and an increased risk of prostate cancer in offspring. The study detected changes in the expression of over 700 genes in offspring, including the gene ABCG1, which is associated with prostate cancer.
A new study by Northwestern University found that lab-trained AI models are easily misled by tissue contaminants, resulting in errors in diagnoses and vessel damage detection. The researchers suggest improving the problem of quantifying and addressing biological impurities in AI models to enhance accuracy.
A 10-year follow-up study of nearly 2,500 U.S. men who received prostate cancer treatment found that adverse effects of treatments on sexual function may be deemphasized in decision making for some men. The study suggests that active surveillance can be a beneficial option for patients with favorable-prognosis prostate cancer.
A Phase 3 clinical trial found that combining testosterone-blocking drugs prevents cancer spread and extends treatment time in patients with relapsed prostate cancer. The approach is more effective than single-drug treatment in delaying cancer progression.
This study explores the perspectives of primary care physicians (PCPs) and urologists on active surveillance (AS) care for men with low-risk prostate cancer. Key findings include the importance of patient education and clear communication among care team members to prevent loss to follow-up.
Researchers developed computational algorithms to analyze patient data and discovered a protein, NME2, that works closely with MYC in advanced prostate cancer cells resistant to enzalutamide. Reducing NME2 levels restored the drug's efficacy, offering new hope for patients who initially respond poorly.
Researchers at Washington State University have discovered a key protein in prostate cancer cells' resistance to docetaxel. Blocking this protein, CHRM1, with dicyclomine restored the effectiveness of docetaxel and reduced tumor growth.
A new study found that Black patients were more likely to choose active surveillance, while those with a strong desire for a cure or expecting longer life with treatment were less likely. Education and urologist interventions can increase active surveillance adoption among low-risk prostate cancer patients.
A study found rectal examinations offer no advantages over PSA blood tests for detecting prostate cancer. The research analyzed data from 85,738 participants and concluded digital rectal examination alone or with PSA is not more effective than the PSA test.
Researchers developed a blood test, NEMO, to detect neuroendocrine prostate cancer (NEPC) and differentiate it from CRPC-adenocarcinoma. The test uses cell-free DNA methylation changes to quantify tumor burden and identify subtypes.
A study in the JAMA Network Open found that Hispanic and American Indian individuals with breast, colorectal, lung, and prostate cancer were undercaptured in the National Cancer Database, but representation improved over time. Further investigation is needed to understand where these populations seek cancer care.
Researchers at UCLA Health have received a $3 million grant to identify novel biomarkers and develop AI for detecting aggressive prostate cancer. The project aims to improve treatment accuracy and reduce unnecessary interventions.
Researchers have made significant progress in understanding the enzyme SMYD3's involvement in prostate cancer's progression to a more aggressive stage. The study found that adding methyl groups to the MAP kinase protein is likely SMYD3's role in driving metastasis, and compounds that can inactivate SMYD3 are already available
Researchers discuss recent advances in blood-based liquid biopsies for prostate cancer interrogation, highlighting key biomarkers like CTCs, ctDNA, and exosomes. The studies suggest that these approaches can aid in predicting tumor recurrence, improving treatment response, and evaluating prognosis.
Two studies led by UCLA researchers reveal how cancer cells use energy to survive and grow, shedding light on why some prostate cancers become resistant to hormone therapy. The findings highlight the importance of considering cell metabolism in developing new cancer treatments, particularly those targeting the androgen receptor.
Researchers have discovered a new approach to targeting transcription factors in prostate cancer by exploiting the formation of protein droplets. This process can be used to inhibit androgen receptor activity, which is essential for the growth and survival of cancer cells.
A new study found Black men diagnosed with advanced stages of prostate cancer are significantly less likely to be prescribed novel hormone therapy compared to white or Latino men. The disparity persisted at five years and beyond, with Black patients receiving this crucial treatment at a lower rate.
Researchers identified a correlation between the HSD3B1 biomarker and resistance to combined hormone therapy and radiotherapy in men with prostate cancer. The study found that high levels of the enzyme led to increased testosterone production, promoting resistance to treatment.
Researchers found that monotherapy with PARP inhibitor olaparib improved radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer who have BRCA gene mutations. Improved responses were observed in hereditary BRCA mutations as well as spontaneous alterations.
Researchers at UNC School of Medicine have pieced together the lesser-known DNA repair pathway, polymerase theta-mediated end joining (TMEJ), which is upregulated in patients with hereditary breast cancer, ovarian cancer, and prostate cancer. The discovery could lead to new therapies for cancer by targeting this pathway.
A new treatment strategy shows promise in preclinical models of advanced prostate cancer with RB1 gene loss or neuroendocrine features. Decitabine and B7-H3 targeted therapy have been shown to slow tumor growth and improve efficacy when combined.
A study found that bone scans overstage prostate cancer at initial staging, leading to potential withholding of definitive therapy from patients. PSMA PET is more accurate than CT and bone scans for staging patients with prostate cancer.
Researchers have identified 451 genetic variants associated with prostate cancer risk through a comprehensive analysis of nearly 950,000 men. The findings improve the accuracy of genetic risk scores and may lead to personalized screening recommendations for men at higher risk.
The PhRMA Foundation awarded two $500,000 Frontier Awards to researchers William Padula and Surachat Ngorsuraches for their patient-centered value assessment models. Their studies will advance the field of value assessment by applying theoretical models in a real-world context and engaging with patients to ensure their voices are inclu...
A new study found that the gut microbiota plays a significant role in prostate inflammation in aging men, particularly those with metabolic syndrome. The researchers discovered a strong relationship between IL-6 and IL-18 expression and lipid parameters in the prostate tissue of men with BPH + MetS.
Researchers found that metformin restores mitochondrial activity and prevents cancer progression in mice and human prostate cells, particularly those with low NKX3.1 levels. The study suggests metformin could be used to prevent further progression of cancer in patients under active surveillance with low-NKX3.1 tumors.
Men who are overweight or obese at age 18 have a higher risk of developing 17 different cancers later in life. Higher BMI is also associated with an increased risk of mortality after cancer diagnosis for certain types of cancer.
Researchers found that a specific gene, MDA-9, initiates a cellular chain reaction sparking prostate cancer metastasis. The study's findings hold significant implications for treating prostate cancer and other forms of disease.
Researchers found that Black men are more likely to have prostate cancer than white men, regardless of PSA level. This highlights the importance of earlier and more frequent screening for Black men to reduce health disparities.
A phase 1 trial of the radiopharmaceutical 225AC-J591 demonstrated promising antitumor activity against advanced metastatic prostate cancer, reducing PSA levels by at least half for 47% of patients. The treatment was well-tolerated, with only temporary low blood cell count side effects.
A new study finds that systemic therapies for advanced prostate cancer are equally effective for Black men as they are for white men, regardless of socioeconomic status. The research suggests that disparities in healthcare can be eliminated with equal access to treatment.
A simple MRI scan and a new metric for prostatic urethra length may help identify men at risk of chronic urinary side effects after radiation therapy. The study found that longer prostatic urethras are associated with a higher likelihood of these symptoms, which can impact quality of life.
Cedars-Sinai Cancer investigators have identified two promising new treatment options for men with recurrent prostate cancer, improving metastasis-free survival and quality of life. The combination therapy reduced the risk of metastasis or death by 58%, while enzalutamide alone was effective in preventing cancer spread or death.
A recent study of nearly 13,000 veterans with nonmetastatic castration-resistant prostate cancer found that Black and Hispanic men have improved outcomes when treated in equal-access settings. The research highlights the need for targeted care to address racial disparities in healthcare outcomes.
Scientists at Mays Cancer Center found that altering androgen receptor multivalent interactions may lead to new treatments for prostate cancer. The study suggests that precise levels of these interactions are crucial for proper hormone-induced gene expression.
Men with metastatic prostate cancer in Sweden experienced an average survival rate increase of six months after dual treatment was introduced from 2016 onwards. This improvement coincides with the gradual rollout of 'dual treatment', combining standard hormone therapy and chemotherapy or androgen receptor blockers.
A new study found that precision medicine navigators can significantly increase genomic testing rates for Black patients with prostate cancer. Genomic testing is used to gauge the likelihood of cancer metastasis and has been shown to be more accurate than traditional tests in predicting treatment outcomes.
A phase III trial suggests that fewer and higher doses of radiation therapy delivered over five sessions are as effective as lower doses delivered over several weeks for patients with locally advanced disease. The treatment achieved a 96% five-year disease control rate, comparable to 95% for conventional radiation.
Researchers found persistent inflammation in intestines of patients 20 years post-radiotherapy, even with targeted treatments. This could lead to chronic symptoms like tenesmus and frequent diarrhea.
The American Society for Radiation Oncology announced the winners of its new combination therapy challenge, which aims to improve prostate cancer treatments using relugolix in combination with radiation therapy. The three winning research proposals will receive funding over four to five years.
A scoping review identified four key themes: everyday language, thorough information, adequate discussion time, and a trusting relationship. The study also highlighted the impact of racism on Black men's medical interactions. Researchers suggest strategies to support men's communication preferences.
Researchers have identified 11 genes associated with aggressive prostate cancer, which could lead to more effective treatments and earlier detection. The findings come from a large-scale study of over 17,500 patients and may help personalize care for individuals with the disease.
A study comparing PI-RADS 2.0 and 2.1 found no significant differences in upgrade (29% vs. 22%) or downgrade (19% vs. 21%) rates from targeted biopsy to radical prostatectomy, suggesting no improvement in prostate cancer grade assessment with the latest PI-RADS update.
Researchers developed a personalized combination treatment that turned on an immunometabolic switch to effectively control aggressive prostate cancer. The treatment showed complete tumor control and long-lasting survival without side effects in a mouse model of advanced prostate cancer.
Researchers identified how prostate cancer cells achieve cell growth free from usual growth cues and regulators. A protein called PLEKHS1 was found to be a major driver of PI3K activation and cancer growth progression in mouse models.
The Society of Nuclear Medicine and Molecular Imaging has issued a new consensus statement to standardize the selection and management of patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with Lu-177 PSMA radionuclide therapy. The statement recommends performing PSMA PET within three months of treatment or sin...
A free online tool can help prostate cancer patients save thousands of dollars in out-of-pocket drug costs by comparing Medicare Part D prescription plans. The Medicare Part D Plan Finder identifies significant savings for patients taking abiraterone or enzalutamide, two common prescription drugs for advanced prostate cancer.
Research published in BMJ Oncology reveals a global increase of 79% in new cancer cases among those under 50 between 1990 and 2019. Breast cancer accounted for the highest number of early onset cases, while cancers of the windpipe and prostate rose the fastest.